Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sorafenib and Topotecan in Platinum-Resistant Ovarian Cancer
NCT00526799Phase 2Terminated
- Start
- Sep 2007
- Primary completion
- Jan 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of sorafenib in ovarian cancer, primary peritoneal carcinoma (PPC), fallopian tube cancer (PFTC). Started Sep 2007; status: terminated.
02
Drugs
sorafenib
03
Conditions
ovarian cancerprimary peritoneal carcinoma (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00526799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00526799.